Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DB7W8H
|
|||
| Drug Name |
rhenium-186
|
|||
| Synonyms |
Rhenium-186; Rhenium Re-186; ZU7F1ET6TM; 14998-63-1; (~186~Re)Rhenium; UNII-ZU7F1ET6TM; 186Re; RHENIUM (186-RE); Rhenium, isotope of mass 186; DTXSID60933825; RHENIUM-186 [WHO-DD]; Q18882928
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Glioblastoma [ICD-11: 2A00] | Phase 1 | [1] | |
| Company |
Plus Therapeutics Austin, TX
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
Re
|
|||
| Canonical SMILES |
[Re]
|
|||
| InChI |
InChI=1S/Re/i1+0
|
|||
| InChIKey |
WUAPFZMCVAUBPE-IGMARMGPSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05460507) A Single Arm Open Label Study to Determine the Safety and Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Recurrence of Glioma in Patients Who Received a Prior Treatment With 186RNL. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.